Gritstone Bio Stock Discussion

$Gritstone Bio(GRTS.US)$ Gritstone Bio (NASDAQ:GRTS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $1.742 million which beat the analyst consensus estimate of $1.104 million by 57.77 percent. This is a 28.69 percent decrease over sales of $2.443 million the same per...

$Gritstone Bio(GRTS.US)$ up up rocket high

$Gritstone Bio(GRTS.US)$
NEWS
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024

$Gritstone Bio(GRTS.US)$Up

$Gritstone Bio(GRTS.US)$
NEWS
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
-- Paper details vaccine design optimization process of Gritstone’s “off-the-shelf” or shared neoantigen vaccine platform, SLATE --
-- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. ...

$Gritstone Bio(GRTS.US)$ Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024 27 MINUTES AGO, 7:00 AM EDT VIA GLOBENEWSWIRE                                                                                                           -- State-of-the-art neoantigen prediction platform (EDGE™) now predicts HLA Class I presentation of epitopes with >80% accuracy -- -- Newly developed EDGE-II model achieves superior predictive performance of HLA Class II presentation...

$Gritstone Bio(GRTS.US)$ something to watch

$Gritstone Bio(GRTS.US)$ Steady rise. Do not miss this again.

$Gritstone Bio(GRTS.US)$ Rising when you least expected. it to.